PTC Therapeutics Net Worth
PTC Therapeutics Net Worth Breakdown | PTCT |
PTC Therapeutics Net Worth Analysis
PTC Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including PTC Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of PTC Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform PTC Therapeutics' net worth analysis. One common approach is to calculate PTC Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares PTC Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing PTC Therapeutics' net worth. This approach calculates the present value of PTC Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of PTC Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate PTC Therapeutics' net worth. This involves comparing PTC Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into PTC Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if PTC Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PTC Therapeutics' net worth research are outlined below:
| PTC Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 2.63 M. | |
| PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
| PTC Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from investorplace.com: PTCT Stock Earnings PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 |
PTC Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in PTC Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PTC Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
PTC Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PTC target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. PTC Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Buy |
Most PTC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand PTC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of PTC Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPTC Therapeutics Target Price Projection
PTC Therapeutics' current and average target prices are 28.57 and 35.42, respectively. The current price of PTC Therapeutics is the price at which PTC Therapeutics is currently trading. On the other hand, PTC Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
PTC Therapeutics Market Quote on 28th of April 2024
Target Price
Analyst Consensus On PTC Therapeutics Target Price
Know PTC Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PTC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PTC Therapeutics backward and forwards among themselves. PTC Therapeutics' institutional investor refers to the entity that pools money to purchase PTC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Franklin Resources Inc | 2023-12-31 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.1 M | Blackstone Inc | 2023-12-31 | 1.1 M | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 998.3 K | Adage Capital Partners Gp Llc | 2023-12-31 | 892.2 K | Pictet Asset Manangement Sa | 2023-12-31 | 866.6 K | D. E. Shaw & Co Lp | 2023-09-30 | 840.8 K | Wellington Management Company Llp | 2023-12-31 | 9.8 M | Vanguard Group Inc | 2023-12-31 | 8.8 M |
Follow PTC Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PTC Therapeutics's market, we take the total number of its shares issued and multiply it by PTC Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project PTC Therapeutics' profitablity
PTC Therapeutics' profitability indicators refer to fundamental financial ratios that showcase PTC Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, PTC Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, PTC Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of PTC Therapeutics' profitability requires more research than a typical breakdown of PTC Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.46) | |
| Return On Capital Employed | (0.27) | (0.26) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | 0.77 | 0.80 |
When accessing PTC Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures PTC Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PTC Therapeutics' profitability and make more informed investment decisions.
The data published in PTC Therapeutics' official financial statements usually reflect PTC Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of PTC Therapeutics. For example, before you start analyzing numbers published by PTC accountants, it's critical to develop an understanding of what PTC Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of PTC Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PTC Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in PTC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PTC Therapeutics. Please utilize our Beneish M Score to check the likelihood of PTC Therapeutics' management manipulating its earnings.
Evaluate PTC Therapeutics' management efficiency
PTC Therapeutics has return on total asset (ROA) of (0.1029) % which means that it has lost $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.80 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.2 B in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (10.94) | (10.39) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (17.11) | (16.25) | |
| Enterprise Value Over EBITDA | (16.70) | (17.53) | |
| Price Book Value Ratio | (2.52) | (2.39) | |
| Enterprise Value Multiple | (16.70) | (17.53) | |
| Price Fair Value | (2.52) | (2.39) | |
| Enterprise Value | 1.9 B | 1.2 B |
The analysis of PTC Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze PTC Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of PTC Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 3.6002 | Revenue 927.6 M | Quarterly Revenue Growth (0.05) | Revenue Per Share 12.281 | Return On Equity (77.40) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PTC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on PTC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PTC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PTC Therapeutics Corporate Filings
| 26th of April 2024 Other Reports | ViewVerify | |
8K | 25th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 22nd of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
PTC Therapeutics Earnings Estimation Breakdown
The calculation of PTC Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of PTC Therapeutics is estimated to be -1.52 with the future projection ranging from a low of -2.66 to a high of -0.91. Please be aware that this consensus of annual earnings estimates for PTC Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.66 Lowest | Expected EPS | -0.91 Highest |
PTC Therapeutics Earnings Projection Consensus
Suppose the current estimates of PTC Therapeutics' value are higher than the current market price of the PTC Therapeutics stock. In this case, investors may conclude that PTC Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and PTC Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2024 | Current EPS (TTM) | |
| 8 | 63.95% | -1.2 | -1.52 | -8.37 |
PTC Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of PTC Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering PTC Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of PTC Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.PTC Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as PTC Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of PTC Therapeutics should always be considered in relation to other companies to make a more educated investment decision.PTC Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact PTC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-06-05 | 2024-03-31 | -1.24 | -1.2 | 0.04 | 3 | ||
2024-03-12 | 2023-12-31 | 0.5 | -2.06 | -2.56 | 512 | ||
2023-10-26 | 2023-09-30 | -1.17 | -1.76 | -0.59 | 50 | ||
2023-08-03 | 2023-06-30 | -1.71 | -2.66 | -0.95 | 55 | ||
2023-04-27 | 2023-03-31 | -1.52 | -1.88 | -0.36 | 23 | ||
2023-02-21 | 2022-12-31 | -1.59 | -1.89 | -0.3 | 18 | ||
2022-10-27 | 2022-09-30 | -1.24 | -1.53 | -0.29 | 23 | ||
2022-08-04 | 2022-06-30 | -1.33 | -2.13 | -0.8 | 60 | ||
2022-05-03 | 2022-03-31 | -1.51 | -1.78 | -0.27 | 17 | ||
2022-02-22 | 2021-12-31 | -1.65 | -2.03 | -0.38 | 23 | ||
2021-10-28 | 2021-09-30 | -1.49 | -1.89 | -0.4 | 26 | ||
2021-07-29 | 2021-06-30 | -1.82 | -1.68 | 0.14 | 7 | ||
2021-05-04 | 2021-03-31 | -1.51 | -1.83 | -0.32 | 21 | ||
2021-02-25 | 2020-12-31 | -0.94 | -1.08 | -0.14 | 14 | ||
2020-10-29 | 2020-09-30 | -0.06 | -1.03 | -0.97 | 1616 | ||
2020-08-05 | 2020-06-30 | -1.3 | -2.62 | -1.32 | 101 | ||
2020-04-30 | 2020-03-31 | -1.33 | -1.81 | -0.48 | 36 | ||
2020-03-02 | 2019-12-31 | -0.51 | -1.37 | -0.86 | 168 | ||
2019-10-29 | 2019-09-30 | -0.76 | -1.06 | -0.3 | 39 | ||
2019-08-06 | 2019-06-30 | -0.58 | -0.75 | -0.17 | 29 | ||
2019-05-02 | 2019-03-31 | -0.76 | -1.29 | -0.53 | 69 | ||
2019-02-28 | 2018-12-31 | -0.32 | -0.58 | -0.26 | 81 | ||
2018-11-05 | 2018-09-30 | -0.4 | -1.06 | -0.66 | 165 | ||
2018-08-07 | 2018-06-30 | -0.29 | -0.21 | 0.08 | 27 | ||
2018-05-09 | 2018-03-31 | -0.43 | -0.46 | -0.03 | 6 | ||
2018-03-06 | 2017-12-31 | -0.14 | 0.03 | 0.17 | 121 | ||
2017-11-02 | 2017-09-30 | -0.68 | -0.82 | -0.14 | 20 | ||
2017-08-08 | 2017-06-30 | -1.28 | -0.44 | 0.84 | 65 | ||
2017-05-08 | 2017-03-31 | -1.03 | -0.85 | 0.18 | 17 | ||
2017-03-16 | 2016-12-31 | -1.07 | -0.78 | 0.29 | 27 | ||
2016-11-02 | 2016-09-30 | -1.22 | -1.03 | 0.19 | 15 | ||
2016-08-04 | 2016-06-30 | -1.27 | -1.14 | 0.13 | 10 | ||
2016-05-05 | 2016-03-31 | -1.26 | -1.22 | 0.04 | 3 | ||
2016-02-29 | 2015-12-31 | -1.24 | -1.5 | -0.26 | 20 | ||
2015-11-09 | 2015-09-30 | -1.15 | -1.27 | -0.12 | 10 | ||
2015-07-30 | 2015-06-30 | -1.2 | -1.14 | 0.06 | 5 | ||
2015-05-04 | 2015-03-31 | -1.2 | -1.15 | 0.05 | 4 | ||
2015-02-27 | 2014-12-31 | -0.82 | -0.84 | -0.02 | 2 | ||
2014-11-06 | 2014-09-30 | -0.9 | -0.93 | -0.03 | 3 | ||
2014-08-07 | 2014-06-30 | -0.74 | -0.86 | -0.12 | 16 | ||
2014-05-06 | 2014-03-31 | -0.46 | -0.58 | -0.12 | 26 | ||
2014-03-06 | 2013-12-31 | -0.57 | -0.75 | -0.18 | 31 | ||
2013-11-14 | 2013-09-30 | -0.3 | -0.19 | 0.11 | 36 | ||
2013-08-12 | 2013-06-30 | -0.77 | -5.51 | -4.74 | 615 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in PTC Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
PTC Therapeutics Corporate Directors
PTC Therapeutics corporate directors refer to members of a PTC Therapeutics board of directors. The board of directors generally takes responsibility for the PTC Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of PTC Therapeutics' board members must vote for the resolution. The PTC Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Emma Reeve | Independent Director | Profile | |
| Stephanie Okey | Independent Director | Profile | |
| Ronald Renaud | Director | Profile | |
| Dawn Svoronos | Director | Profile |
How to buy PTC Stock?
The net worth of PTC Therapeutics is the difference between its total assets and liabilities. PTC Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of PTC Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. PTC Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if PTC Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in PTC Therapeutics stock.Already Invested in PTC Therapeutics?
The danger of trading PTC Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of PTC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than PTC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile PTC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether PTC Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if PTC Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ptc Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Ptc Therapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.281 | Quarterly Revenue Growth (0.05) | Return On Assets (0.10) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.